Philip J. Young, Osteologix' President and Chief Executive Officer commented, "I am very happy that we have been able to reach agreement on this important collaboration. This endorsement from one of the top Pharmaceutical Companies worldwide is appropriate recognition for NB S101 and its value in treating osteoporosis. Servier is consistently recognized as a benchmark for excellence in the pharmaceutical industry, having received multiple industry accolades for its attention to patients' and doctors' needs, and successful clinical development of 'first in class' innovations. We fully expect this history of excellence to continue, as they prepare for the commercial launch of NB S101."

Emmanuel Canet, M.D., Ph.D., Head of Servier Research and Development, stated, "We are very pleased with this collaboration which will allow us to further develop our franchise in osteoporosis and other bone & joint diseases that affect millions of patients worldwide with much suffering and disability. Osteoporosis in particular is a serious public health problem that requires effective and well tolerated treatments in order to significantly decrease the risk of vertebral and hip fractures."

SOURCE Osteologix, Inc.